Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
NAD⁺ & NMN
Video summary

Video description on NAD+, NMN and NR in longevity research

The description presents a video about NAD+, its reported decline with age, sirtuins and David Sinclair's Harvard research, and asks whether NR or NMN works, citing 2025/2026 studies and a supplement-market warning. These are the creator's claims; the video and transcript were not reviewed. [1]

Automatic summary · not editorially reviewed

The key findings

  1. The description says the video covers NAD+, described as the most abundant molecule in the body after water, and its role in cell survival. [1]

  2. The description states that NAD+ levels drop 50% every 20 years after adulthood and links NAD+ to sirtuins and David Sinclair's Harvard research. [1]

  3. The description announces a comparison of NR and NMN, cites 2025/2026 studies, and promises protocols plus a supplement-market warning. [1]

The source at a glance

Study type / format
Video description
Population / context
Viewers of a longevity video; no study population is specified in the description.
Summary based on
Creator description
Original publication
July 30, 2026

NAD+ and sirtuins as described

According to the description, the video examines NAD+, called the most abundant molecule in the body after water, and why it is said to be essential for cell survival. It links NAD+ to sirtuins and the so-called longevity genes, attributed to David Sinclair's Harvard research. The description also says NAD+ levels drop 50% every 20 years after adulthood. These are the creator's statements in the description, not findings verified here.

Supporting source [1]

NR versus NMN and cited studies

The description says the video compares nicotinamide riboside (NR) with nicotinamide mononucleotide (NMN) and asks which one works. It lists a systematic review in Ageing Research Reviews (2026), a phase II trial in Alzheimer's & Dementia (2025), a randomized double-blind placebo-controlled trial on medRxiv (2026) and University of Oslo research reported by ScienceDaily (2026). The description gives no results, participant numbers or outcome measures, so no effect can be judged from it.

Supporting source [1]

Protocols and supplement-market warning

The description announces science-backed protocols covering dosages, exercise and intermittent fasting, and a warning about the billion-dollar supplement market with what the Cleveland Clinic recommends. It also promises David Sinclair's revelation in Dubai and asks whether science is close to making aging reversible. The description includes a disclaimer that the content is informational and based on scientific research and advises consulting a physician or nutritionist before any supplementation. No protocol details or recommendations are given in the description itself.

Supporting source [1]

How to interpret this

Only the video description was available; the video and transcript were not reviewed. All details are the creator's claims, and no study results, participant numbers or outcomes are reported in the description.

Based on the creator’s description; the full video and transcript were not analyzed.

Source & supporting passages

[1]
NMN and NAD+: The Science of Longevity | What Harvard Discovered

THE LONGEVITY CODE · youtube.com · July 30, 2026

Read the quoted passagesIn the language of the original source
  1. Finding 1 ↑

    the most abundant molecule in your body
  2. Finding 2 ↑

    How NAD+ levels drop 50% every 20
  3. Finding 3 ↑

    Nicotinamide Riboside (NR) vs Nicotinamide Mononucleotide (NMN)

AI-assisted summary with linked source passages. No independent editorial or clinical review.

Our editorial method

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…